Lennox International Inc. (LII), engaged in heating, air conditioning, and refrigeration businesses, raised FY12 EPS and revenue guidance above estimates.
- Raises FY12 adjusted EPS expectations from ongoing operations to $2.60-2.80 from $2.35-2.65. Consensus $2.51.
- Raises FY12 GAAP EPS from continuing operations guidance to a range of $2.55-$2.75 from $2.30-$2.60.
- Raises FY12 revenue growth expectations to a range of 5-7% from 3-6% at constant currency. Assuming a negative 1 point impact from foreign exchange on a full-year basis, the company sees revenue growth of 4-6% at actual currency. Consensus negative growth of 0.5%.
Supernus Pharmaceuticals Inc. (SUPN) said its experimental epilepsy drug Oxtellar XR won FDA approval. This is the second drug approval for the company since its May IPO. In June, the company won tentative approval on Trokendi XR, another epilepsy treatment. Oxtellar is slated for launch in the first quarter of 2013.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.